Tumor-associated lipid antigen

Tumor-associated lipid antigens are a heterogeneous group of lipid molecules derived from, or associated with, tumor cells[1][5]. These lipids can be presented on the cell surface by the molecule CD1d (a non-classical MHC class I-like antigen-presenting molecule), enabling their recognition by type I invariant NKT (iNKT) cells and other immune cell subsets[1]. The structural features important for immune recognition include the hydrophobic acyl chains buried within specific binding pockets of CD1d, and hydrophilic head groups that are exposed for T cell receptor (TCR) recognition[1]. The repertoire of tumor-derived lipid antigens can directly affect the activation profile of NKT cells and, therefore, anti-tumor immunity[1][3][5]. Abnormal lipid metabolism or altered lipid composition within the tumor microenvironment can also impact antigen presentation, affect dendritic cell function, and contribute to immune evasion by tumors[3][4][5]. However, "tumor-associated lipid antigen" does not refer to a unique molecular entity; rather, it is a descriptive, functional category encompassing various lipids (such as glycolipids, phospholipids, and sphingolipids) found in tumors, some of which can be immunogenic and may serve as candidate targets for immunotherapy[1][5]. There is no standardized molecular identity, no official abbreviation, and no direct list of approved drugs or biomarkers targeting "tumor-associated lipid antigen." The term is generally used in the scientific literature to describe lipids that are abnormally present or presented in tumors and can participate in immune modulation. This makes it an imprecise "target" by drug discovery or immunology standards, and should not be listed as a unique, actionable molecular target.

Other names

tumor lipid antigentumor lipid-associated antigenTALA